by The primary sclerosing cholangitis (PSC) market includes products such as ursodeoxycholic acid, obeticholic acid, and other treatment therapies. PSC is a rare liver disorder characterized by chronic inflammation and scarring of the bile ducts that causes bile to build up in the liver. Over time, the built-up bile damages the bile ducts and liver tissues. Early diagnosis, progression monitoring and effective treatment are critical to improving the quality of life of PSC patients.
The Market is estimated to be valued at US$ 2.29 Mn in 2024 and is expected to exhibit a CAGR of 5.0% over the forecast period from 2024 to 2030.
Key Takeaways
Key players operating in Global Primary Sclerosing Cholangitis Market Size are Volkswagen Group, BMW Group, Mercedes-Benz (Daimler AG), Audi (Volkswagen Group), Ford Motor Company, General Motors, Toyota Motor Corporation, Honda Motor Co. Ltd., Hyundai Motor Group, Kia Motors Corporation, Nissan Motor Co. Ltd., Mazda Motor Corporation, Subaru Corporation, Volvo Cars, Peugeot SA. Key players are increasingly investing in R&D to develop novel treatment therapies for effective management of the disease.
The growing prevalence of PSC globally is propelling the demand for advanced treatment therapies in the market. According to statistics, about 12 per 100,000 people are affected by PSC in North America and Europe. Moreover, lack of effective cure and progression to liver cirrhosis and liver cancer over time is anticipated to drive the uptake of available treatment options.
Owing to the increasing R&D activities globally, available treatment options for PSC are expanding to international markets. Leading players are actively pursuing geographical expansion strategies including collaborations and licensing agreements to penetrate developing as well as untapped markets.
Market Key Trends
Increased adoption of combination therapies is a key trend gaining traction in the primary sclerosing cholangitis market. Previous treatment failure with monotherapy and need for synergistic efficacy has led to clinical research evaluating combinations of obeticholic acid with ursodeoxycholic acid or other agents. Combination regimens are expected to provide improved treatment outcomes over monotherapy alone for better management of PSC.
Porter’s Analysis
Threat of new entrants: Very high barriers to entry as high capital investment required for R&D and manufacturing.
Bargaining power of buyers: Moderate bargaining power of buyers as customized products are available from different manufacturers.
Bargaining power of suppliers: High bargaining power of suppliers due to specialized raw materials and components required.
Threat of new substitutes: Threat of substitutes is low as no close substitutes are available.
Competitive rivalry: High competitive rivalry among existing competitors to gain market share by launching new products and expanding geographically.
Geographical Regions:
North America accounts for the largest share of the primary sclerosing cholangitis market in terms of value owing to increasing prevalence of inflammatory bowel diseases, increasing awareness regarding sclerosing cholangitis, and presence of major market players in the region.
Asia Pacific is expected to witness fastest growth in the primary sclerosing cholangitis market during the forecast period due to growing healthcare spending, rising incidence of inflammatory bowel diseases and liver diseases, improving healthcare infrastructure, and presence of generic manufacturers in the region.
